TORONTO, Ontario – May 17, 2007: AtheroMedix Inc. (“AtheroMedix”) today announced that it has changed its corporate name to AIM Therapeutics Inc. (“AIM Therapeutics”).

“The Company’s technologies have been enhanced as a result of the merger with Salpep Biotechnology in February 2007”, said Dr. Richard Timmer, President & CEO of AIM Therapeutics. “AIM, which stands for Advanced Immune Modulation, more accurately represents the company’s broadened technology platforms.”

The company has a new logo and corporate identity and is developing a new web site that will be launched in July 2007 to keep its investors and partners up to date on the progress of its development programs.

About AIM Therapeutics:

AIM Therapeutics is a privately held biotechnology company focused on the development of peptide-based therapeutic candidates for the treatment of asthma, cardiovascular disease, diabetes, spinal cord injury, and other inflammatory and immune disorders. Our therapeutic candidates are based on research from leading scientists at the University of Western Ontario, the University of Calgary and the University of Alberta. AIM Therapeutics is pursuing the pre-clinical validation and development of its lead candidates through a virtual business model being managed by BioQuest Innovations Inc.